Treatment for chronic hepatitis C: A phase II study

Jan 15, 2010

The current standard treatment for chronic hepatitis C with pegylated-interferon (PEG-IFN) and ribavirin is effective in approximately 50%-60% of patients, so that a substantial proportion of patients remain unresponsive. A rational approach to develop alternative therapeutic strategies for patients with chronic hepatitis C virus (HCV) infection demands a detailed knowledge of how the different drugs affect viral kinetics and IFN intracellular signaling. Non-steroidal antiinflammatory drugs (NSAIDs) have been demonstrated to amplify the IFN signaling pathways and to enhance the anti-viral effect of IFN.

Based on previous data, a research team from Italy evaluated the safety of adding ketoprofen to pegylated-interferon (PEG-IFN) with or without ribavirin and the effect on viral kinetics, signal transducer and activator of transcription 1 (STAT1) activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS) in 1 chronic in a phase Ⅱ study. Their study will be published on December 21, 2009 in the World Journal of Gastroenterology.

Their research found that the addition of ketoprofen to the conventional combination therapy is associated with better viral kinetics and early activation of the IFNa , thus improving virological response rates. The authors postulated that a larger trial should be done with this three-drug combination, compared to the standard of care.

Explore further: 40 states, district of columbia reporting respiratory virus that targets kids

More information: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase Ⅱ study. World J Gastroenterol 2009; 15(47): 5946-5952 www.wjgnet.com/1007-9327/15/5946.asp

add to favorites email to friend print save as pdf

Related Stories

New treatment option for patients with chronic hepatitis C

May 28, 2009

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive ...

Discovery could improve hepatitis C treatment

Sep 23, 2009

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit ...

New treatment therapy helps inhibit hepatitis C

Jul 31, 2008

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on beh ...

Good news for some hard-to-treat hepatitis C patients

Jun 16, 2009

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to ...

Recommended for you

Ebola-hit Liberia staring into the abyss

3 hours ago

With its collapsed health service, sick and poorly equipped security forces and broken economy, Ebola-hit Liberia finds itself on the brink of complete societal breakdown, experts warn.

Dallas hospital monitoring patient for Ebola

3 hours ago

A patient in a Dallas hospital is showing signs of the Ebola virus and is being kept in strict isolation with test results pending, hospital officials said Monday.

'Deadly diarrhea' rates nearly doubled in 10 years

13 hours ago

Infections with the intestinal superbug C. difficile nearly doubled from 2001 to 2010 in U.S. hospitals without noticeable improvement in patient mortality rates or hospital lengths of stay, according to a study of 2.2 mi ...

User comments : 0